Aurora Cannabis vs Rigel Pharmaceuticals
Rigel Pharmaceuticals is the larger business, with $294m of revenue in fiscal 2025 against $232m for Aurora Cannabis (1.3 times as much). Rigel Pharmaceuticals grew faster (64.1% against 11.7%). Rigel Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 124.7% against -42.4%. Aurora Cannabis carries less debt relative to equity (0.0% against 13.4%).
| Latest fiscal year | Aurora CannabisACB, 2026 | Rigel PharmaceuticalsRIGL, 2025 |
|---|---|---|
| Revenue | $232m | $294m |
| Revenue growth | 11.7% | 64.1% |
| Net income | −$98.4m | $367m |
| Operating margin | — | 42.6% |
| Net margin | -42.4% | 124.7% |
| Return on equity | -25.9% | 185.9% |
| Free cash flow | −$9.8m | $75.7m |
| Cash | $46.4m | $40.6m |
| Total debt | $0 | $52.5m |
| Debt to equity | 0.0% | 13.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $295m | $889m |
| Price vs our value range | — | Below our value range |
| Moat score | — | 29 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 3 sales |